AR069539A1 - Avances respecto de las formulaciones de comprimidos contra el vih - Google Patents

Avances respecto de las formulaciones de comprimidos contra el vih

Info

Publication number
AR069539A1
AR069539A1 ARP080103204A ARP080103204A AR069539A1 AR 069539 A1 AR069539 A1 AR 069539A1 AR P080103204 A ARP080103204 A AR P080103204A AR P080103204 A ARP080103204 A AR P080103204A AR 069539 A1 AR069539 A1 AR 069539A1
Authority
AR
Argentina
Prior art keywords
against hiv
regarding formulations
core
tablets against
advances regarding
Prior art date
Application number
ARP080103204A
Other languages
English (en)
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of AR069539A1 publication Critical patent/AR069539A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Una formulacion de comprimido contra el VIH que incluye un nucleo que contiene de 0,1 a 1,5% en peso (p/p) de dioxido de silicio coloidal y 0,4 a 0,9% en peso (p/p) de un lubricante, el resto del nucleo está compuesto por darunavir, un desintegrante y un relleno que comprende una mezcla secada por pulverizacion de celulosa microcristalina y dioxido de silicio coloidal, estando el nucleo opcionalmente recubierto con un recubrimiento de película.
ARP080103204A 2007-07-25 2008-07-24 Avances respecto de las formulaciones de comprimidos contra el vih AR069539A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113104 2007-07-25

Publications (1)

Publication Number Publication Date
AR069539A1 true AR069539A1 (es) 2010-02-03

Family

ID=38666812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103204A AR069539A1 (es) 2007-07-25 2008-07-24 Avances respecto de las formulaciones de comprimidos contra el vih

Country Status (12)

Country Link
US (1) US20100189783A1 (es)
EP (1) EP2182926A2 (es)
JP (1) JP2010534222A (es)
CN (1) CN101820865A (es)
AR (1) AR069539A1 (es)
AU (1) AU2008278974A1 (es)
BR (1) BRPI0814602A2 (es)
CA (1) CA2693235A1 (es)
IL (1) IL202651A0 (es)
NZ (1) NZ600472A (es)
RU (1) RU2010106616A (es)
WO (1) WO2009013356A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2493891A2 (en) * 2009-10-30 2012-09-05 Lupin Limited A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
WO2011141921A1 (en) * 2010-05-10 2011-11-17 Hetero Research Foundation Darunavir compositions
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination products
BR112014000195A2 (pt) * 2011-07-07 2017-02-21 Janssen R&D Ireland formulações de darunavir
EP3496719B1 (en) 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
WO2018029561A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
US20090028938A1 (en) * 2005-08-08 2009-01-29 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
BRPI0618529A2 (pt) * 2005-11-11 2011-09-06 Tihomir Lelas meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro

Also Published As

Publication number Publication date
WO2009013356A2 (en) 2009-01-29
RU2010106616A (ru) 2011-08-27
CA2693235A1 (en) 2009-01-29
CN101820865A (zh) 2010-09-01
IL202651A0 (en) 2010-06-30
NZ600472A (en) 2013-09-27
EP2182926A2 (en) 2010-05-12
JP2010534222A (ja) 2010-11-04
BRPI0814602A2 (pt) 2015-01-27
AU2008278974A1 (en) 2009-01-29
US20100189783A1 (en) 2010-07-29
WO2009013356A3 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
PE20142368A1 (es) Formas de dosificacion del tapentadol novedosas y potentes
AR069539A1 (es) Avances respecto de las formulaciones de comprimidos contra el vih
CL2019000209A1 (es) Formulación novedosa administrable por la vía oral.
MX340591B (es) Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
NO20073601L (no) Immunresponsmodifikator-skumformuleringer
MX2010007609A (es) Formulacion de capsula.
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
PE20200478A1 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion
BR112015025015A2 (pt) composições de formação de película para o revestimento com película de formas sólidas
WO2011056741A3 (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
DK2178513T3 (da) Sammensætninger i tabletform indeholdende atazanavir
BR112019012099A2 (pt) composições e métodos de higiene bucal para branqueamento dos dentes
HRP20100120T1 (hr) Formulacije s valsartanom
NO20071485L (no) Kjemiske substanser.
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
ECSP099611A (es) Composiciones farmaceuticas que comprenden un agente calcilitico
PE20150888A1 (es) Composicion de difenidol de liberacion prolongada
CO6321223A2 (es) Formulacion farmaceutica solida que contiene ciclostazol
PE20142460A1 (es) Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel
JP2015129124A5 (es)
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
BR112019002040A2 (pt) revestimentos fáceis de engolir e substratos revestidos com os mesmos
BR112015028302A2 (pt) formulação de pastilha de nicotina
CR20150320A (es) Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil) etil]-h-pirazol-3-il]-4-[(3r, 5s)-3,5-dimetilpiperazin-1-il]benzamida
WO2019004984A3 (en) PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL

Legal Events

Date Code Title Description
FA Abandonment or withdrawal